Wednesday, July 8, 2026

pharma · Epilepsy · Allergic Reaction · AQST

Aquestive Therapeutics

Aquestive Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker AQST. Primary therapeutic focus areas include Epilepsy, Allergic Reaction, Nausea and Vomiting, Postoperative

Vancouver, CA HQ
2009 Founded
75 Employees
Public company Type
AQST · NYSE Ticker
Company details
Status
Public
HQ
Vancouver, CA
Founded
2009
Employees
75
Programs
9
Drugs
9
Patents
17
Clinical program

Diazepam Buccal Film 12.5 mg

Phase 2 · small molecule · Epilepsy

Diazepam Buccal Film 12.5 mg for Epilepsy is a Phase 2 program (small_molecule) at Aquestive Therapeutics with 1 ClinicalTrials.gov record(s).

← All Aquestive Therapeutics projects Phase 2 small molecule completed

Internal code 160326

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Aquestive Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Epilepsy
Status
completed
Trials
1